Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
PRNewswire (Mon, 30-Mar 7:03 AM ET)
Market Chameleon (Mon, 16-Mar 6:29 AM ET)
PRNewswire (Fri, 13-Mar 7:01 AM ET)
Market Chameleon (Tue, 10-Mar 6:29 AM ET)
PRNewswire (Mon, 9-Mar 8:01 AM ET)
PRNewswire (Mon, 16-Feb 8:01 AM ET)
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
PRNewswire (Mon, 2-Feb 8:00 AM ET)
Acurx Unveils Promising Microbiome-Sparing Antibiotics: Class Effect May Revolutionize CDI Treatment
Market Chameleon (Tue, 28-Oct 5:09 AM ET)
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Acurx Pharmaceuticals trades on the NASDAQ stock market under the symbol ACXP.
As of March 30, 2026, ACXP stock price declined to $3.50 with 355,441 million shares trading.
ACXP has a beta of -0.09, meaning it tends to be less sensitive to market movements. ACXP has a correlation of 0.00 to the broad based SPY ETF.
ACXP has a market cap of $9.99 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ACXP traded as high as $176.40 and as low as $1.33.
The top ETF exchange traded funds that ACXP belongs to (by Net Assets): VXF.
ACXP has underperformed the market in the last year with a price return of -58.7% while the SPY ETF gained +12.7%. However, in the short term, ACXP had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.7% vs -8.2% return in SPY. But in the last 2 weeks, ACXP shares have been beat by the market, returning -9.8% compared to an SPY return of -4.3%.
ACXP support price is $3.25 and resistance is $4.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACXP shares will trade within this expected range on the day.
